Patients with type 2 diabetes are characterised not only by compromised insulin secretion and action, but also by elevated plasma concentrations of the 29-amino acid peptide hormone glucagon, which generally is thought of as a pancreas-derived hormone (produced in and secreted from alpha cells in the islet of Langerhans). In patients with diabetes, circulating glucagon concentrations are elevated in the fasting state and fail to decrease appropriately or even increase in response to ingestion of nutrients. Glucagon is known to be a potent stimulator of hepatic glucose production, and, thus, the elevated glucagon concentrations in diabetes contribute decisively to the predominating trait of patients with diabetes namely hyperglycaemia. Interestingly, studies have shown that while oral intake of glucose results in inappropriately high plasma concentrations of glucagon in patients with diabetes, intravenous (iv) infusion of glucose does not. The mechanisms behind these differential glucagon responses to oral vs. iv glucose administration are currently unexplained. Three hypotheses were tested in the present thesis: 1) Could the inappropriate glucagon response to oral glucose ingestion in patients with diabetes be attributed to the release of glucagonotropic/glucagonostatic peptides secreted from the gut? 2) Could the inappropriate glucagon response to oral glucose ingestion in diabetes be a result of extrapancreatic glucagon secretion (possibly originating from the gut)? And 3) Does the differential glucagon responses between oral and iv glucose administration affect endogenous glucose production (EGP). The overall aim of this PhD thesis was, thus, to investigate the role of the gut in diabetic hyperglucagonaemia and hyperglycaemia. In Study I we examined the effect of the three gut-derived hormones glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) on glucagon secretion in patients with type 2 diabetes. We applied a 50 g-oral glucose tolerance test (OGTT), and five isoglycaemic iv glucose infusions (IIGIs) with either saline, GIP, GLP-1, GLP-2 or a combination of the three hormones. We show that these gut-derived hormones affect glucagon secretion differently and that OGTT-induced secretion of these hormones may play a role in the inappropriate glucagon response to orally ingested glucose in patients with type 2 diabetes with especially GIP acting to increase glucagon secretion. In Study II we examined totally pancreatectomised patients and non-diabetic control subjects during a 75 g-OGTT and an IIGI. We applied sandwich enzyme-linked immunosorbent assay (ELISA) and mass spectrometry-based proteomics for plasma glucagon analysis and show that 29-amino acid glucagon circulates in patients without a pancreas and that glucose stimulation of the gut results in significant hyperglucagonemia in these patients - ultimately confirming the existence of extrapancreatic glucagon secretion in humans. In Study III we examined whether the different responses of insulin and glucagon, respectively, between oral and iv glucose administration translate into differences in EGP and glucose disappearance in patients with type 2 diabetes and non-diabetic control subjects. We applied glucose tracer methodology during a 75 g-OGTT, IIGI and IIGI + iv glucagon (to isolate the effect of glucagon) and show that EGP is less suppressed during OGTT than during IIGI in both patients with type 2 diabetes and non-diabetic control subjects.